The FDA has drafted new guidelines aimed at cutting the development process for new flu vaccines by one to two years. These guidelines outline the data that developers will need to provide to gain the agency's approval. The FDA has been pushing a variety of new measures aimed at speeding the development process. The change includes a fresh look at live virus treatments delivered through a nasal spray. The agency is particularly interested in fostering new technology for the speedier introduction of vaccines that can fight both traditional flu as well as a possible bird flu pandemic.
- read this AP report for more information
PLUS: Australia's Biota says it is well positioned to earn royalties from the huge demand that has developed for the anti-influenza drug Relenza. Report
ALSO: With countries around the globe shunning French poultry in the wake of a bird flu outbreak, the country's poultry industry is losing $48 million a month. Report